Therefore, a bifunctional protein in which the extracellular domain of TGF-β type II receptor (a TGF-β trap) is fused to anti-PD-L1 antibody is currently under evaluation in clinical trials to treat cancer (289). Here, TGFB1 is linked to cancer.